drugset / Trial / NCT00157573

GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer

NCT00157573 ↗

Non-randomizedSequentialOpen-labelTreatment

Summary

Granulocyte macrophage colony-stimulating factor (GM-CSF) is an immunostimulant and preliminary data suggests it may change the natural history of prostate cancer and melanoma. This study looks at ability of GM-CSF to alter disease progression in women who have recurrent but asymptomatic recurrence of their ovarian cancer.

Timeline

Start
2004-12
Primary completion
2008-10
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject sargramostim Protein / enzyme biologic 150 ug/m2 Subcutaneous
Subject sargramostim Protein / enzyme biologic 250 ug/m2 Subcutaneous